Latest News:- Pneumococcal Vaccine Market: Pneumococcal conjugate vaccine is expected to lead the Type segment during 2024-2028

Pneumococcal Vaccine Market to grow at a CAGR of 5.6% during 2024-2028

The Pneumococcal Vaccine Market is expected to grow at a CAGR of 5.6% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 2845.2 million. The global pneumococcal vaccine market has experienced notable progressions, with the introduction of advanced vaccine technologies leading to more effective and efficient preventive measures against pneumococcal diseases. One such innovation is the development of conjugate vaccines, which incorporate polysaccharides from the pneumococcal bacteria's outer coating linked to a carrier protein. This enhancement enables a stronger and longer-lasting immune response from the body. An illustrative example is the 13-valent pneumococcal conjugate vaccine (PCV13), which has been extensively utilized in various countries due to its enhanced immunogenicity. 

Get more information on Pneumococcal Vaccine Market by requesting a sample report

The Pneumococcal conjugate vaccine subsegment is expected to dominate the Type segment during the forecast period 

Technavio analysts predict that the Pneumococcal conjugate vaccine subsegment will lead the Type segment during 2024 and 2028 The Pneumococcal Vaccine Market represents a significant business opportunity due to the increasing global burden of pneumococcal diseases. Key players in this market are focusing on developing more effective and affordable vaccines to cater to the growing demand. Innovative approaches, such as conjugate vaccines, are being employed to enhance vaccine efficacy and broaden protection against various strains. Market growth is further fueled by government initiatives and collaborations between industry players and research institutions.

Here are the various ways based on which the market is segmented: 

• Type
  • Pneumococcal conjugate vaccine
  • Pneumococcal polysaccharide vaccine
• Distribution Channel
  • Non-governmental organizations
  • Government authorities
  • Distribution partner companies
• Geography
  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

Reasons to Purchase the Global Pneumococcal Vaccine Market Market Research Report by Technavio. What is in it for you?

• Wealth of Experience: Technavio is an established name in the world of market research. It holds an expertise of more than 20 years in the field, has published 21,000+ reports thereby extensively covering the area in various industries and range of regions
• Insight into Current Market Trends: Our research reports provide our readers insights into the latest market intelligence, competitor strategies, market trends, changes taking place in the industry and customer preferences, forecasted market opportunities that influence them to make better business decisions
• High ROI with Extensive Hands-on Research: Technavio is renowned for offering personalized market research reports as per unique business needs, delving deep into specific markets, product segments and demographics. Additionally, it is also well-known for providing high return on investments through its wide collection of data at pocket-friendly rates

There are several factors that are causing the market to flourish expanding immunization programs by government in developing countries

Learn which are the obstacles that the market is experiencing in the way of its growth by accessing the free PDF report

Research Analysis Overview

The Pneumococcal vaccine market has gained significant prominence in recent years due to the high burden of pneumococcal diseases, which include bacterial meningitis, pneumonia, and other invasive infections. According to the World Health Organization (WHO), pneumococcal diseases cause an estimated 1.6 million deaths each year, with the highest mortality rates and hospitalizations occurring in demographic groups with economic disparities. The economic burden of these diseases is further compounded by the prevalence of pneumococcal strains that cause disease in individuals with underlying conditions such as Human Immunodeficiency Virus (HIV), Diabetes, Chronic heart disease, Lung disease, and Sinusitis. The manufacturing of pneumococcal vaccines, particularly protein-based vaccines, has been a focus of research activities and pipeline studies to address the evolving threat of novel pneumococcal strains and reduce the burden of pneumococcal diseases. However, vaccine accessibility remains a challenge, especially in low-income countries, where economic disparities limit access to immunization programs. Pneumococcal diseases can affect various parts of the body, including the brain covering (meninges), bloodstream, and lungs, leading to conditions such as Bacterial meningitis, Generalized musculoskeletal infection, and pneumonia. The pandemic potential of invasive pneumococcal disease and the high mortality rates associated with pneumococcal Pneumonia underscore the importance of continued research and vaccine development efforts.

Market Research Overview

The global pneumococcal vaccine market is a significant segment of the larger pharmaceuticals industry, encompassing entities involved in research and development (R&D) or manufacturing of various drug categories, including generics, non-generics, and veterinary drugs. According to Technavio, the healthcare market size is determined by the consolidated revenue generated by providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. The expansion of the global pharmaceuticals market will be fueled by several key factors, most notably the increasing global population aging. By 2050, approximately one-quarter of the US population and by 2030 in Europe, are projected to be over the age of 60 years, leading to a substantial rise in demand for preventative healthcare solutions, such as pneumococcal vaccines.

The Pneumococcal Vaccine Market is experiencing significant growth, fueled by the expanding immunization programs by government in developing countries. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/